Soligenix to Present at the World Orphan Drug Congress
PRINCETON N.J. April 12 2017 PRNewswire Soligenix Inc. Nasdaq SNGX Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare...
View ArticleImmune Pharmaceuticals Announces 1for20 Reverse Stock Split
NEW YORK April 12 2017 PRNewswire Immune Pharmaceuticals Inc. Nasdaq IMNP "Immune" or the "Company" today announced a reverse stock split of its shares of common stock at a ratio of 1for20. Beginning...
View ArticleArticles Induction therapy with the selective interleukin23 inhibitor...
In this shortterm study risankizumab was more effective than placebo for inducing clinical remission in patients with active Crohn's disease. Therefore selective blockade of interleukin23 via...
View ArticleComment Targeting interleukin 23 for Crohn's disease finding the right drug...
Brian Feagan and colleagues1 report in The Lancet the shortterm 12 weeks efficacy and safety of risankizumab a humanised monoclonal antibody targeting the p19 subunit of interleukin 23 in patients with...
View ArticleIntelGenx and RedHill Biopharma Announce Marketing Approval of RIZAPORTR for...
SAINT LAURENT QUEBEC Marketwired 041317 IntelGenx Corp. TSX VENTURE IGXOTCQX IGXT "IntelGenx" a leading oral drug delivery company primarily focused on the development and manufacturing of innovative...
View ArticleCrohn's Admissions Persist Despite New Treatments
MedPage Today No change from 2003 to 2013 according to CDC
View ArticleMetabolomic Technologies Inc Medical Equipment Deals and Alliances Profile...
SummaryMetabolomic Technologies Inc MTI is a biotechnology company that develops metabolomicbased diagnostic systems. The company's products include ColoDx PolypDx BreastDx ProstateDx CeliacDx...
View ArticleNew Meds Make Inroads Against Crohn's Disease
THURSDAY April 13 2017 Fewer Americans with Crohn's disease are ending up in the hospital than in the past according to a new federal study.Crohn's is a chronic inflammatory bowel disorder that often...
View ArticleTillotts Pharma AG Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryTillotts Pharma AG Tillotts a subsidiary of Zeria Pharmaceutical Co Ltd is a pharmaceutical company. It develops licenses and markets pharmaceutical products medical devices and diagnostics in...
View ArticleCrohn's Disease Hospitalization Rates Stable Despite New Drugs
New CDC data show a possible reversal in the trend of increasing Crohn's hospitalizations but also suggest that the availability of new drugs has not translated into fewer hospital admissions. Medscape...
View ArticleCalciMedica Inc Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryCalciMedica Inc CalciMedica is a pharmaceutical company that focuses on the development of small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant...
View ArticleCrohn's Disease Regional Enteritis Pipeline Review H1 2017 Updated 22032017...
Crohn's Disease Regional Enteritis Pipeline Review H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease Regional Enteritis Pipeline Review...
View ArticleArena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at...
SAN DIEGO April 17 2017 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA a biopharmaceutical company focused on developing novel small molecule drugs across multiple therapeutic areas today announced...
View ArticleSonarMD Receives PTAC Recommendation to Advance the Case for Specialty...
The American Medical Association is extremely pleased that Project Sonar is the first alternative payment model nationally to be recommended to the HHS Secretary by the PFPM Technical Advisory...
View ArticleArena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO April 17 2017 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA today announced that it intends to offer and sell subject to market and other conditions shares of its common stock in an...
View ArticleFDA Grants Genentechs TECENTRIQ Atezolizumab Accelerated Approval as Initial...
First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy Genentech a member of the Roche Group SIX RO ROG; OTCQX...
View ArticleArena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO April 17 2017 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA today announced the pricing of an underwritten public offering of 60000000 shares of its common stock offered at a price to the...
View ArticlePharmaceutical Industry Executive Brian W. Andersen Named Chief Business...
MIAMI LAKES FL Marketwired 041817 Asana Medical Inc. "Asana" the "Company" a regenerative medicine company that is developing a novel treatment for Inflammatory Bowel Disease "IBD" including Ulcerative...
View ArticleRedHill Biopharma Receives Notice of Allowance for Two Additional U.S....
RedHill received Notices of Allowance from the United States Patent and Trademark Office USPTO for two new patents covering BEKINDAÂ RHB102 expected to be valid until at least 2034 once granted...
View Article